DALLAS, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil” or the “Company”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for

Related Keywords

Dallas , Texas , United States , , Nasdaq , Instil Bio Inc , Company Quarterly Report On Form , Nasdaq Capital Market , Nasdaq Capital , Co Stimulatory Antigen Receptor , Private Securities Litigation Reform Act , Quarterly Report , Region ,